[ad_1]
This article is over a month old and may contain outdated advice from authorities regarding coronary heart disease.
Stay up-to-date on the NRK overview or on the FHI website.
Several countries have introduced a temporary suspension of the use of the coronary vaccine from the Swedish-British company AstraZeneca.
The reason is that several countries have reported suspected serious side effects among those vaccinated.
In Norway, a woman under the age of 50 died on Sunday. The woman had a rare combination of blood clots, low platelet counts, and bleeding. Two others are still in the hospital with similar symptoms.
Alert statement
The World Health Organization (WHO) and the European Medicines Agency (EMA) have so far recommended continuing vaccination while investigating reports of side effects.
However, Norway and 14 other countries have chosen to stop vaccination altogether pending a response. Other countries have stopped single-delivery vaccination.
Today, the WHO advisory committee and EMA experts met to discuss the situation.
EMA director Emer Cook told a press conference that it is too early to conclude.
“We take the situation seriously and are investigating all the possible side effects of this vaccine,” Cook said at a news conference.
Only on Thursday is the EMA expected to come to a conclusion on what kind of measures should be implemented.
I need facts
Emer Cook says they currently have no basis for saying that it is the vaccine that causes severe blood clots.
– We have hired several experts with blood diseases as a specialty. This is an ongoing process and we will inform the public as soon as we have reached a conclusion, Cook says.
Cook says it is not unexpected that there are reports of rare and serious consequences related to mass vaccination.
– But now we have to gather all the facts to be able to draw a conclusion, says Cook.
When asked if those who have had a blood clot may have been genetically determined, the director of the EMA responds.
– We receive details on several of the cases on an ongoing basis. From what we understand, the side effects may be related to genetic subgroups, but it is too early to draw a conclusion about it.
